Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Sara M. Tolaney et al.|Annals of Oncology|2023Cited by 77
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.Kyriakos P. Papadopoulos, Glenn S. Kroog, Filipa Lynce et al.|Journal of Clinical Oncology|2019Cited by 38
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.Rachel O. Abelman, Laura M. Spring, Shannon McLaughlin et al.|Journal of Clinical Oncology|2025Cited by 11
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancerAlexander P. Gottlieb, Jennifer L. Guerriero, Gregory J. Baker et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1